Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 11;15(2):147.
doi: 10.3390/toxins15020147.

Efficacy and Safety of Botulinum Toxin B in Focal Hyperhidrosis: A Narrative Review

Anna Campanati  1 , Federico Diotallevi  1 , Giulia Radi  1 , Emanuela Martina  1 , Barbara Marconi  1 , Ivan Bobyr  1 , Annamaria Offidani  1
Affiliations
Review

Efficacy and Safety of Botulinum Toxin B in Focal Hyperhidrosis: A Narrative Review

Anna Campanati et al. Toxins (Basel). .

Abstract

Botulinum toxin type B (BoNT-B), known as Myobloc® in the United States and as Neurobloc® in Europe, is a new therapeutically available serotype among the botulinum toxin family. During the last years several data have been reported in literature investigating its efficacy and safety, as well as defining the dosing and application regiments of BoNT-B in the treatment of hyperhidrosis. Moreover, recent studies have been examining its safety profile, which may be different from those known about BoNT-A. The aim of this review is to provide information about what is currently known about BoNT-B in regards to the treatment of focal hyperhidrosis.

Keywords: axillary hyperhidrosis; botulinum toxin type B; compensatory hyperhidrosis; craniofacial hyperhidrosis; focal hyperhidrosis; palmar hyperhidrosis; plantar hyperhidrosis; residual hyperhidrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart on BoNT-B in focal hyperhidrosis. Research dates range from 1999 to 2022 [32]. Reasons for excluding manuscripts: (1) articles including, but not specifically related to focal hyperhidrosis; (2) articles including, but not specifically related to BoNT-B; (3) articles not related to humans; (4) review or expert opinion manuscripts.
See this image and copyright information in PMC

References

    1. Campanati A., Martina E., Giuliodori K., Consales V., Bobyr I., Offidani A. Botulinum Toxin Off-Label Use in Dermatology: A Review. Ski. Appendage Disord. 2017;3:39–56. doi: 10.1159/000452341. - DOI - PMC - PubMed
    1. Brin M.F. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Off. J. Am. Assoc. Electrodiagn. Med. 1997;20:146–168. doi: 10.1002/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4. - DOI - PubMed
    1. Stanley E.F., Drachman D.B. Botulinum toxin blocks quantal but not non-quantal releasee of ACh at the neuro-muscular junction. Brain Res. 1983;261:172–175. doi: 10.1016/0006-8993(83)91300-8. - DOI - PubMed
    1. Baumann L.S., Halem M.L. Botulinum toxin-B and the management of hyperhidrosis. Clin. Dermatol. 2004;22:60–65. doi: 10.1016/j.clindermatol.2003.11.001. - DOI - PubMed
    1. Birklein F., Eisenbarth G., Erbguth F., Winterholler M. Botulinum Toxin Type B Blocks Sudomotor Function Effectively: A 6 Month Follow Up. J. Investig. Dermatol. 2003;121:1312–1316. doi: 10.1046/j.1523-1747.2003.12620.x. - DOI - PubMed

Substances